Literature DB >> 29685759

Can low grade PMP be divided into prognostically distinct subgroups based on histological features? A retrospective study and the importance of using the appropriate classification.

Aditi Bhatt1, Suniti Mishra2, Robin Prabhu3, Veena Ramaswamy2, Antony George4, Sonal Bhandare5, Mita Shah5, Sanket Mehta6.   

Abstract

INTRODUCTION: The pathological classification of PMP of appendiceal origin has prognostic and treatment implications. Our goals were to • Classify low grade mucinous carcinoma peritonei (LGMCP) into prognostically distinct subgroups based on histological features. • Compare the reproducibility of the WHO and the PSOGI classifications for both PMP and the appendiceal primary tumor. PATIENTS AND METHODS: A retrospective analysis of patients undergoing CRS and HIPEC or debulking surgery was done. All the tumors were re-classified according to the PSOGI classification. LGMCP was further classified into three histological subgroups and the impact on survival was evaluated.
RESULTS: From Jun 2011 to June 2016, 101 patients underwent CRS with HIPEC (n = 89) or debulking surgery (n=12). The median PCI was 28 (3-39) and 74.1% patients had CC-0/1 resections. Of the 76.2% patients who had LGMCP, 4 patients (5.1%) were classified as group 1, 54 (70.1%) as group 2 and 19 patients (24.6%) as group 3. At a median follow up of 21 months, the disease free survival was not reached, 30 months and 14 months for groups 1, 2 and 3 respectively (p = 0.09). There was no difference in overall survival. Using the WHO classification, there was a discordance in the grade of the primary tumor and the peritoneal lesions in 19.8% and conflicting terminology was used in 62% of patients.
CONCLUSIONS: The subgroups of LGMCP described here are prognostically different though this needs further prospective evaluation in larger series. The PSOGI classification is more uniformly reproducible and should be preferred to the WHO classification.
Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Low grade PMP; Mucinous appendiceal tumors; PMP classification; PSOGI classification

Mesh:

Substances:

Year:  2018        PMID: 29685759     DOI: 10.1016/j.ejso.2018.03.032

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

1.  From the Ronnett to the PSOGI Classification System for Pseudomyxoma Peritonei: A Validation Study.

Authors:  Blanca Rufián-Andujar; Francisca Valenzuela-Molina; Sebastián Rufián-Peña; Ángela Casado-Adam; Juan Manuel Sánchez-Hidalgo; Lidia Rodríguez-Ortiz; Francisco Javier Medina-Fernández; Cesar Díaz-López; Rosa Ortega-Salas; Ana Martínez-López; Javier Briceño-Delgado; Antonio Romero-Ruíz; Álvaro Arjona-Sánchez
Journal:  Ann Surg Oncol       Date:  2021-01-20       Impact factor: 5.344

2.  Validating the PSOGI classification of peritoneal disease from non-carcinoid epithelial appendiceal neoplasms in the curative and palliative setting: an observational retrospective study.

Authors:  Nina Farrokhnia; Henrik Benoni; Lana Ghanipour; Peter H Cashin
Journal:  J Gastrointest Oncol       Date:  2022-04

Review 3.  Essentials for Pathological Evaluation of Peritoneal Surface Malignancies and Synoptic Reporting of Cytoreductive Surgery Specimens-A review and evidence-based guide.

Authors:  Aditi Bhatt; Suniti Mishra; Loma Parikh; Sandeep Sheth; Imran Gorur
Journal:  Indian J Surg Oncol       Date:  2019-03-19

4.  Updated staging and patient outcomes in low-grade appendiceal mucinous neoplasms.

Authors:  Samuel J Ballentine; Jacquelyn Carr; Eliahu Y Bekhor; Umut Sarpel; Alexandros D Polydorides
Journal:  Mod Pathol       Date:  2020-07-29       Impact factor: 7.842

5.  Tumor-stroma ratio as a new prognosticator for pseudomyxoma peritonei: a comprehensive clinicopathological and immunohistochemical study.

Authors:  Ru Ma; Yu-Lin Lin; Xin-Bao Li; Feng-Cai Yan; Hong-Bin Xu; Zheng Peng; Yan Li
Journal:  Diagn Pathol       Date:  2021-12-13       Impact factor: 2.644

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.